Prostate Cancer, Version 3.2024
Edward M. Schaeffer(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Sandy Srinivas(Cancer Institute (WIA)), Nabil Adra(Indiana University Melvin and Bren Simon Comprehensive Cancer Center), Yi An(Yale Cancer Center), Rhonda L. Bitting(Cancer Institute (WIA)), Brian F. Chapin(The University of Texas MD Anderson Cancer Center), Heather H. Cheng(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Anthony V. D’Amico(Dana-Farber Brigham Cancer Center), Neil Desai(Southwestern Medical Center), Tanya B. Dorff(City Of Hope National Medical Center), James A. Eastham(Memorial Sloan Kettering Cancer Center), Thomas A. Farrington(Education and Research Network), Xīn Gào(Massachusetts General Hospital), Shilpa Gupta(Cleveland Clinic), Thomas Guzzo(University of Pennsylvania), Joseph E. Ippolito(Barnes-Jewish Hospital), R. Jeffrey Karnes(WinnMed), Michael Kuettel(Roswell Park Comprehensive Cancer Center), Joshua M. Lang(University of Wisconsin Carbone Cancer Center), Tamara L. Lotan(Sidney Kimmel Comprehensive Cancer Center), Rana R. McKay(UC San Diego Health System), Todd M. Morgan(University of Michigan), Julio M. Pow‐Sang(Moffitt Cancer Center), Robert E. Reiter(University of Colorado Cancer Center), Mack Roach(UCSF Helen Diller Family Comprehensive Cancer Center), Tyler P. Robin(University of Colorado Cancer Center), Stan Rosenfeld(University of California, San Francisco), Ahmad Shabsigh(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Daniel E. Spratt(Cleveland Clinic), Russell Z. Szmulewitz(University of Chicago Medicine Comprehensive Cancer Center), Benjamin A. Teply(Susan Thompson Buffett Foundation), Jonathan D. Tward(University of Utah), Richard K. Valicenti(UC Davis Comprehensive Cancer Center), J.K. Wong(Fox Chase Cancer Center), Jenna Snedeker(National Comprehensive Cancer Network), Deborah A. Freedman-Cass(National Comprehensive Cancer Network)
Cited by 263Open Access
Abstract
The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic disease. These NCCN Guidelines Insights summarize the panel's discussions for the 2024 update to the guidelines with regard to initial risk stratification, initial management of very-low-risk disease, and the treatment of nonmetastatic recurrence.
Related Papers
No related papers found
Powered by citation graph analysis